COMPANY PROFILE

Novartis

Explore full profile

To discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering

Basel, SwitzerlandFounded 1970Biotech & Life Sciences

Valuation $314B Market cap · 2026

Revenue $58B Latest reported FY

EBITDA $23B Latest reported FY

About Novartis

Novartis is een farmaceutisch bedrijf dat streeft naar het leveren van een betekenisvolle bijdrage aan de gezondheidszorg. Door gebruik te maken van op wetenschap gebaseerde innovaties, proberen we betere behandelresultaten voor patiënten over de hele wereld te realiseren. In onze zoektocht naar nieuwe medicijnen behoren we consequent tot 's werelds topbedrijven, die investeren in onderzoek en ontwikkeling. Wereldwijd bereiken de producten van Novartis bijna 1 miljard mensen. Door te voldoen aan de veranderende behoeften van patiënten proberen wij de kwaliteit van leven te verbeteren en de levensduur te verlengen. Er werken wereldwijd ongeveer 110.000 mensen met 149 nationaliteiten bij Novartis.

Read full description

Bij Novartis Nederland werken rond de 400 mensen. Als team One Novartis Amsterdam zetten we ons iedere dag met enthousiasme en passie in voor onze missie: Reimagine Medicine.

Klik hier voor onze community guidelines: http://bit.ly/2JnT2CP.

Source: Dealroom company data

At a glance

Status: Listed
Founded: 1970
Headquarters: Basel, Switzerland
Listing: IPO 1995
Employees: 85,665
Open positions: 153
Dealroom signal: 68.4/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Innovation Management, Developer Tools, Biotechnology, Patient Care, Biotech and Pharma, EIT KIC Partners, Horizon Europe
Business model: Manufacturing
Client focus: b2b, b2c
Investment activity: 106 companies, latest Sep 2026
Capital deployed: $3.4B
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO DEBT✓Debt	Nov 2025	$6B	—	Undisclosed	↗
GRANT✓Other financing	Feb 2018	$6.5M	—	Bill & Melinda Gates Foundation	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$58B	+1.8%	$23B	40.4%	$14B	24.6%	$11B
2025	$57B	+9.6%	$23B	40.8%	$14B	24.7%	$11B
2024	$52B	+10.8%	$21B	40.5%	$12B	23.1%	$10B
2023	$47B	-10%	$18B	39.6%			$11B
2022	$52B	-2%	$16B	31.6%
2021	$53B	+6%	$33B	62.5%
2020	$50B	—	$17B	34.5%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Novartis website traffic

Latest recorded traffic for Novartis is 670K monthly website visits, up 17.5% over the last three months. Novartis's team declined 9.6% over the past year.

Latest monthly visits670K 3-month web change+17.5% 1-year team growth-9.6%

Monthly website visitsDec 2016–Oct 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Validation LeadMorrisville, NC · Other · Oct 3, 2026 Allergy Territory Account Specialist – Flint, MISaginaw, MI · Accounting · Oct 3, 2026 Allergy Territory Account Specialist – Flint, MIField, MN · Accounting · Oct 3, 2026 Site Robotics LeadKundl, Tyrol, Austria · Data Science & Engineering · Oct 2, 2026 Managed Care Claims AnalystEast Hanover, NJ · Accounting · Oct 2, 2026 Associate Director, US InsuranceEast Hanover, NJ · Other · Oct 2, 2026 Director, Deployment Strategist, Applied AIBasel, Switzerland · Project Management · Oct 2, 2026 Executive Director, Pricing & ContractingBasel, Switzerland · Accounting · Oct 2, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DEDeliniaFounded to discover and develop novel therapeutics for the treatment of autoimmune and inflammatory diseases	San Francisco, United States	Acquired	—	$35M	$300M
ZPZealand PharmaDiscovery, design and development of innovative peptide-based medicines	Søborg, Denmark	Operational
HTHoba TherapeuticsDeveloper of neuropathic pain and CNS therapies. The company develops biopharmaceuticals for chronic pain and hearing loss	Copenhagen, Denmark	Operational
4S4SCThe development of novel drugs for the treatment of cancer	Planegg, Germany	Operational
SPSealife PharmaSealife Pharma GmbH is an innovative drug development company	Tulln, Austria	Operational
GAGadetaDevelopment of innovative immunotherapies for cancer	Utrecht, Netherlands	Acquired
MMMove in MedDevelops and markets digital tools and innovative services for healthcare professionals to coordinate the care of patients with chronic diseases	Baillargues, France	Operational
OPOptimataOptimata uses high-level, multiscale modeling that integrates rational analysis of treatment mechanisms with information from large databases to develop solutions for predicting an oncology patient’s prognosis and the benefit they may gain from drug	Bnei Atarot, Israel	Operational